Group One Trading
BTAI

Group One Trading’s BioXcel Therapeutics BTAI Stock Holding History

Group One Trading’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,100
Closed -$6.56K – 7692
2025
Q4 		$6.56K Hold
4,100
– – ﹤0.01% 7051
2025
Q3 		$10.5K Sell
4,100
-4,300
-51% -$13.6K ﹤0.01% 7139
2025
Q2 		$15.2K Hold
8,400
– – ﹤0.01% 6443
2025
Q1 		$17.1K Buy
8,400
+7,450
+784% +$27.8K ﹤0.01% 5923
2024
Q4 		$5.68K Buy
950
+425
+81% +$3.55K ﹤0.01% 6360
2024
Q3 		$5.12K Sell
525
-450
-46% -$6.05K ﹤0.01% 5870
2024
Q2 		$20K Sell
975
-2,606
-73% -$87.2K ﹤0.01% 5230
2024
Q1 		$162K Sell
3,581
-807
-18% -$38.5K ﹤0.01% 3736
2023
Q4 		$207K Buy
4,388
+3,413
+350% +$190K ﹤0.01% 3832
2023
Q3 		$39.5K Sell
975
-16,775
-95% -$1.7M ﹤0.01% 5321
2023
Q2 		$1.89M Buy
17,750
+17,494
+6,834% +$5.83M 0.01% 1762
2023
Q1 		$76.5K Sell
256
-557
-69% -$238K ﹤0.01% 4526
2022
Q4 		$279K Sell
813
-1,800
-69% -$435K ﹤0.01% 3565
2022
Q3 		$494K Buy
2,613
+1,913
+273% +$444K ﹤0.01% 3246
2022
Q2 		$148K Buy
700
+94
+16% +$19.8K ﹤0.01% 4593
2022
Q1 		$203K Sell
606
-2,725
-82% -$790K ﹤0.01% 4780
2021
Q4 		$1.08M Buy
3,331
+2,806
+534% +$1.2M ﹤0.01% 3278
2021
Q3 		$255K Sell
525
-144
-22% -$63.3K ﹤0.01% 4916
2021
Q2 		$311K Buy
669
+425
+174% +$232K ﹤0.01% 4750
2021
Q1 		$168K Sell
244
-1,575
-87% -$1.27M ﹤0.01% 5198
2020
Q4 		$1.34M Buy
1,819
+188
+12% +$146K ﹤0.01% 2375
2020
Q3 		$1.13M Buy
1,631
+275
+20% +$206K ﹤0.01% 2079
2020
Q2 		$1.15M Buy
1,356
+1,137
+519% +$741K 0.01% 1898
2020
Q1 		$78K Buy
+219
New +$78.7K ﹤0.01% 3459

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Group One Trading's BTAI Position: Q2 2026 in Review

Group One Trading held its BioXcel Therapeutics (BTAI) position steady in Q2 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #7466.

Group One Trading first reported a position in BTAI in Q1 2020 and has held it in 21 quarters since. The position peaked at $1.3M in Q2 2020. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Group One Trading held 1 share of BioXcel Therapeutics worth $1 as of Q2 2026.
  • Group One Trading left its BioXcel Therapeutics share count unchanged in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #7466 holding.
  • Group One Trading first reported a position in BioXcel Therapeutics in Q1 2020 and has held it in 21 quarters since.
  • Group One Trading's BioXcel Therapeutics position peaked at $1.3M in Q2 2020.
  • 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.